However, one study by Lucarelli et al. showed that treatment of human osteosarcoma cells with the PPARγ agonist troglitazone promotes the in vitro survival via reduction in apoptosis of the malignant cells [170]. The gene discussed is PPARG; the disease is osteosarcoma.